Human immunodeficiency virus-associated lipodystrophy: An objective definition based on dual-energy x-ray absorptiometry-derived regional fat ratios in a south Asian population

Endocrine Practice

Volumn 18, Issue 2, 2012, Pages 158-169

  Asha, Hesarghatta Shyamasunder ^a   Seshadri, Mandalam Subramaniam ^a   Paul, Thomas Vizhalil ^a   Abraham, Ooriapadickal Cherian ^a   Rupali, Priscilla ^a   Thomas, Nihal ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ZIDOVUDINE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE PREDISPOSITION; DUAL ENERGY X RAY ABSORPTIOMETRY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FAT BODY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEAN BODY WEIGHT; LEG; MALE; METABOLIC PARAMETERS; NOMENCLATURE; POSTPRANDIAL STATE; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SKINFOLD THICKNESS; SOUTH ASIA; TRIACYLGLYCEROL BLOOD LEVEL; TRICEPS BRACHII MUSCLE; TRUNK; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ABDOMINAL FAT; ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADIPOSITY; ADULT; AMBULATORY CARE FACILITIES; ANTHROPOMETRY; ARM; ASIA; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INDIA; INSULIN RESISTANCE; LOWER EXTREMITY; MALE; MASS SCREENING; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SKINFOLD THICKNESS;

EID: 84859848378     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11139.OR     Document Type: Article

References (25)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al (HIV Outpatient Study Investigators). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Shevitz A, Wanke CA, Falutz J, Kotler DP. Clinical perspectives on HIV-associated lipodystrophy syndrome: An update [published correction appears in AIDS. 2002;16: 307]. AIDS. 2001;15:1917-1930.
3. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
4. Carr A, Emery S, Law M, Puis R, Lundgren JD, Powderly WG (HIV Lipodystrophy Case Definition Study Group). An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet. 2003;361:726-735.
5. Brown TT. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab. 2008;93:2937-2945.
6. Schwenk A. Methods of assessing body shape and composition in HIV-associated lipodystrophy. Curr Opin Infect Dis. 2002;15:9-16.
7. Haarbo J, Gotfredsen A, Hassager C, Christiansen C. Validation of body composition by dual energy X-ray absorptiometry (DEXA). Clin Physiol. 1991;11:331-341.
8. Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr. 1990;51:1106-1112.
9. Bonnet E, Delpierre C, Sommet A, et al. Total body composition by DXA of 241 HIV negative men and 162 HIV infected men: Proposal of reference values for defining lipodystrophy. J Clin Densitom. 2005;8:287-292.
10. Freitas P, Santos AC, Carvalho D, et al. Fat mass ratio: An objective tool to define lipodystrophy in HIV-infected patients under antiretroviral therapy. J Clin Densitom. 2010;13:197-203.
11. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in western India. J Acquir Immune Defic Syndr. 2005;39:199-202.
12. Saghayam S, Chaguturu SK, Kumarasamy N, Solomon S, Mayer KH, Wanke C. Lipoatrophy is the predominant presentation of HIV-associated lipodystrophy in southern India. Clin Infect Dis. 2004;38:1646-1647.
13. Padmapriyadarsini C, Swaminathan S, Karthipriya MJ, Narendran G, Menon PA, Thomas BE. Morphologic and body composition changes are different in men and women on generic combination antiretroviral therapy-an observational study. J Assoc Physicians India. 2010;58:375-377.
14. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2007. http://www.who.int/hiv/pub/guidelines/ HIVstaging150307.pdf. Accessed for verification September 29, 2011.
15. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41 (RR-17):1-19.
16. Hall JG, Allanson JE, Gripp KW, Slavotinek AM. Handbook of Physical Measurements. 2nd ed. New York, NY: Oxford University Press, 2007: 50-71.
17. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15-E26.
18. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487-1495.
19. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (American Heart Association; National Heart, Lung, and Blood Institute). Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109:433-438.
20. Fernandes AP, Sanches RS, Mill J, Lucy D, Palha PF, Dalri MC. Lipodystrophy syndrome associated with antiretroviral therapy in HIV patients: Considerations for psychosocial aspects. Rev Lat Am Enfermagem. 2007;15: 1041-1045.
21. Ammassari A, Antinori A, Cozzi-Lepri A, et al (AdICoNA Study Group; LipoICoNA Study Group). Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr. 2002;31(suppl 3):S140-S144.
22. Duran S, Savès M, Spire B, et al (APROCO Study Group). Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS. 2001;15:2441-2444.
23. Milinkovic A, Martinez E. Current perspectives on HIV-associated lipodystrophy syndrome. J Antimicrob Chemother. 2005;56:6-9.
24. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study [published correction appears in Arch Intern Med. 2005;165:2541]. Arch Intern Med. 2005;165:1179-1184.
25. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet. 1999;353:2093-2099.